Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Zevra Therapeutics ( (ZVRA) ).
On December 2, 2025, Zevra Therapeutics announced the appointment of Alicia Secor to its Board of Directors, following the resignation of Wendy Dixon, PhD. Secor, with over thirty years of experience in the life sciences industry, is expected to contribute significantly to the company’s strategic goals and shareholder value. Dixon’s departure was amicable, with no disagreements with the company’s operations, policies, or practices.
The most recent analyst rating on (ZVRA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.
Spark’s Take on ZVRA Stock
According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.
Zevra Therapeutics’ overall score is driven by strong revenue growth and reasonable valuation, offset by significant challenges in profitability and cash flow management. Technical indicators suggest a bearish trend, but the company’s strategic initiatives and robust financial position provide a foundation for future growth.
To see Spark’s full report on ZVRA stock, click here.
More about Zevra Therapeutics
Zevra Therapeutics, Inc. is a commercial-stage company dedicated to addressing unmet needs in the treatment of rare diseases. The company focuses on developing and commercializing life-changing therapeutics for people living with rare conditions, utilizing data-driven strategies to overcome complex drug development challenges.
Average Trading Volume: 1,900,380
Technical Sentiment Signal: Sell
Current Market Cap: $469.5M
Learn more about ZVRA stock on TipRanks’ Stock Analysis page.